E2 ModeratePreliminaryPEM not requiredCross-SectionalPeer-reviewedReviewed
Standard · 3 min
Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling.
Biswal, Bharat, Kunwar, Pratap, Natelson, Benjamin H · Journal of the neurological sciences · 2011 · DOI
Quick Summary
Researchers used a brain imaging technique called arterial spin labeling to measure blood flow in the brains of 11 ME/CFS patients and 10 healthy people. They found that ME/CFS patients as a group had significantly lower blood flow to their brains compared to healthy controls, though this pattern wasn't universal—some patients showed normal or even slightly increased blood flow. This suggests that reduced brain blood flow may be one physical feature of ME/CFS, though it doesn't affect all patients in the same way.
Why It Matters
This study provides objective neuroimaging evidence that ME/CFS has a measurable biological substrate in the brain—specifically altered cerebral blood flow—which supports the legitimacy of ME/CFS as a neurological condition. The confirmation of findings using two different imaging methods strengthens confidence in this observation, and the identification of heterogeneous responses may help explain why ME/CFS symptoms and severity vary among patients.
Observed Findings
ME/CFS patients as a group had significantly lower global cerebral blood flow compared to healthy controls.
Reductions in CBF were observed across nearly every brain region assessed in the patient group.
9 of 11 ME/CFS patients showed decreased CBF relative to control template data.
2 of 11 ME/CFS patients showed increased CBF relative to controls, indicating heterogeneous responses.
Absolute CBF measurement by ASL replicated earlier findings from xenon-CT studies.
Inferred Conclusions
CFS patients demonstrate broad decreases in cerebral blood flow compared to healthy controls, suggesting a neurological substrate to the disease.
The effect of reduced CBF is not homogeneous across all ME/CFS patients, implying possible disease heterogeneity or distinct patient subgroups.
Using absolute rather than relative CBF measurement, combined with case-by-case analysis, may be important for detecting neurobiological differences in this condition.
Remaining Questions
What clinical or demographic characteristics distinguish the 2 patients with increased CBF from the 9 with decreased CBF, and do these groups have different symptom profiles?
Does the magnitude of CBF reduction correlate with symptom severity, disease duration, or post-exertional malaise?
What This Study Does Not Prove
This study does not prove that reduced cerebral blood flow causes ME/CFS symptoms—it only shows an association. The study does not establish whether CBF changes are a primary cause, a secondary consequence of the disease, or related to another underlying mechanism. The small sample size and lack of clinical correlation data limit ability to determine which patients' symptoms are most related to their CBF changes.
Tags
Symptom:Fatigue
Biomarker:Neuroimaging
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Are CBF changes stable over time, or do they fluctuate with disease activity and symptom exacerbation?
What mechanisms cause the reduction in cerebral blood flow—autonomic dysfunction, mitochondrial insufficiency, vascular abnormalities, or other factors?